Adams, Richard - Cardiff University

个人简介

Richard Adams is Reader and Consultant Clinical Oncologist at Cardiff University and Velindre Cancer Centre. He is Director of Cancer Trials for the Centre for Trials Research and Director of the Wales Cancer Bank. His clinical practice and research is focused on lower gastrointestinal cancers. He is chair of the National Cancer Research Institute anorectal cancer and CTRad WS2 (UK radiotherapy research) subgroups. He is active in national and international research organisations including IRCI the International Rare Cancer Initiative (for anal cancer) and ARCAD. Richard chairs the biomarker development group for the UK phase III FOCUS4 trial in metastatic colorectal cancer and is Chief investigator for the FOCUS4 D trial. He leads on the radiotherapy quality assurance programme for the UK ARISTOTLE and SAILOR trials. He has a role within Wales to engage researchers in translational research and leads work package 3 of the Wales Cancer Research Centre. He oversees collaborative translational research in numerous phase II/ III colorectal cancer trials. He was a founder member of and now chairs the South Wales Cancer Care link with Sierra Leone.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Sharma, R.et al. 2016. Clinical development of new drug-radiotherapy combinations. Nature Reviews Clinical Oncology 13, pp. 627-642. (10.1038/nrclinonc.2016.79) pdf Hendry, M.et al. 2016. Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations. BMJ Open 6(4), article number: e011205. (10.1136/bmjopen-2016-011205) Hendry, M.et al. 2016. Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations. BMJ Open 6(4), article number: e011205. (10.1136/bmjopen-2016-011205) Ciardiello, F.et al. 2016. Awareness, understanding, and adoption of precision medicine to deliver personalized treatment for patients with cancer: a multinational survey comparison of physicians and patients. The Oncologist 21(3), pp. 292-300. (10.1634/theoncologist.2015-0279) Morris, E.et al. 2016. Wide variation in the use of radiotherapy in the management of surgically treated rectal cancer across the English National Health Service. Clinical Oncology 28(8), pp. 522-531. (10.1016/j.clon.2016.02.002) pdf Grenader, T.et al. 2016. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study. British Journal of Cancer 114(6), pp. 612-615. (10.1038/bjc.2016.23) Renfro, L.et al. 2016. Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. Journal of Clinical Oncology 34(2), pp. 144-150. (10.1200/JCO.2015.61.6441) Hubbard, G.et al. 2016. Is referral of postsurgical colorectal cancer survivors to cardiac rehabilitation feasible and acceptable? A pragmatic pilot randomised controlled trial with embedded qualitative study. BMJ Open 6(1), article number: e009284. (10.1136/bmjopen-2015-009284) Richman, S.et al. 2015. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology 69(1), pp. 35-41. (10.1136/jclinpath-2015-203097) pdf